AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20070756
Drug: Osstem SSII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osstem SSII Implant system
Trial: 20070756
Drug: Standard Straumann
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Straumann Dental Implant System
Trial: 9084336
Drug: Chlorhexidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine administration method 1
Trial: 9084336
Drug: Chlorhexidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine administration method 2
Trial: 1831083
Drug: SCH 34826
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 34826 400 mg
Trial: 1831083
Drug: SCH 34826
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 34826 800 mg
Trial: 1831083
Drug: SCH 34826
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 34826 1600 mg
Trial: 26272719
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of 2% prilocaine (60 mg)
Trial: 26272719
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of 0.4% plain ropivacaine (12 mg)
Trial: 19205780
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of beta-glucan
Trial: 19205780
Drug: Beta-glucan content
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan content (0, 2.5, 5, 7.5, and 10 g)
Trial: 15590253
Drug: Oral fiberoptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fiberoptic intubation
Trial: 11755552
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Trial: 11755552
Drug: Diabetes on
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes on treatment (insulin)
Trial: 11755552
Drug: Diabetes on
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes on treatment (oral medications)
Trial: 9203680
Drug: Antiparasitic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparasitic therapy
Trial: 7963049
Drug: Structured medication
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured medication education
Trial: 7963049
Drug: Unstructured medication
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstructured medication education
Trial: 30987917
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta 0.5 mg/kg 2-weekly
Trial: 30987917
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta 1.0 mg/kg 4-weekly
Trial: 27862727
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of type A botulinum toxin (BoNTA)
Trial: 27862727
Drug: Intradermal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal saline solution injection (Control)
Trial: 17692742
Drug: Candesartan and
RxNorm normalized name: candesartan and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan and spironolactone (combination group)
Trial: 11526203
Drug: Malaria DNA
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria DNA vaccine administered by needle i.m. or needleless jet injection
Trial: 9817534
Drug: Long-term treatments
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatments for multiple sclerosis
Trial: 7544030
Drug: Paclitaxel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (up to 250 mg/m2) followed by Carboplatin (up to 400 mg/m2)
Trial: 7544030
Drug: Carboplatin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (300 mg/m2) with Paclitaxel (200 mg/m2)
Trial: 7544030
Drug: Paclitaxel (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (250 mg/m2) with Carboplatin (350 mg/m2)
Trial: 7544030
Drug: Paclitaxel (above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (above 200 mg/m2)
Trial: 2652281
Drug: Six-month therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six-month therapy with a fixed combination of 120 mg rifampicin, 50 mg isoniazid, and 300 mg pyrazinamide (Rifater)
Trial: 2652281
Drug: Present Swiss
RxNorm normalized name: Swiss Kriss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present Swiss standard therapy (Daily rifampicin, isoniazid, and ethambutol for 2 months followed by rifampicin and isoniazid for 7 months)
Trial: 788758
Drug: Pindolol administered
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol administered once daily
Trial: 788758
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered once daily
Trial: 788758
Drug: Beta-adrenoceptor blocking
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoceptor blocking drugs (general)
Trial: 23168523
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg BID)
Trial: 30863471
Drug: USG bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG bilateral subcostal TAP block with 0.3 ml/kg bupivacaine
Trial: 30863471
Drug: USG bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG bilateral QL block with 0.3 ml/kg bupivacaine
Trial: 21390582
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage of Astragalus granule (7.5 g)
Trial: 21390582
Drug: Moderate dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dosage of Astragalus granule (4.5 g)
Trial: 21390582
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage of Astragalus granule (2.25 g)
Trial: 17261465
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg)
Trial: 17443000
Drug: Interleukin-2-based immunotherapy
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2-based immunotherapy
Trial: 3528979
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone
Trial: 11440296
Drug: Postal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postal and telephone reminders during the first 2 months of pravastatin treatment
Trial: 9754889
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg in D5W
Trial: 8058228
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg twice daily) for two 2-day courses, first at 24 weeks' gestation and second at 29 weeks if G vaginalis was present.
Trial: 2702513
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of nasally applied budesonide twice daily
Trial: 2702513
Drug: 250 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 micrograms of orally administered budesonide twice daily
Trial: 769572
Drug: Pyrimethamine 75
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrimethamine 75 mg and sulfadoxine 1,500 mg
Trial: 769572
Drug: Pyrimethamine 50
RxNorm normalized name: pyrimethamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine 50 mg and diformyldapsone 800 mg
Trial: 10481867
Drug: Intron-A (interferon-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intron-A (interferon-alpha 2b) at standard doses (5 IU/m2/day)
Trial: 10481867
Drug: Low-dose interferon-alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interferon-alpha-2b (reaferon and intron-A, 1-3 IU/m2/day) in combination with chemotherapy
Trial: 18637534
Drug: Zinc therapy
RxNorm normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc therapy
Trial: 23448393
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery by MDLAP
Trial: 21314329
Drug: Curcumin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin administration
Trial: 19824094
Drug: NaHCO3 infusion
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaHCO3 infusion
Trial: 10783014
Drug: aP vaccine
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aP vaccine
Trial: 10783014
Drug: TdaP‐IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TdaP‐IPV vaccine
Trial: 10783014
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of acellular pertussis vaccine
Trial: 8854782
Drug: Arterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arterial infusion (AI) chemotherapy
Trial: 1616115
Drug: Droperidol (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.075 mg/kg)
Trial: 1616115
Drug: Metoclopramide (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.15 mg/kg)
Trial: 1616115
Drug: NaCl (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (0.1 ml/kg)
Trial: 29767728
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg andecaliximab every 2 weeks (Q2W)
Trial: 29767728
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg andecaliximab weekly (QW)
Trial: 29767728
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg andecaliximab Q2W and QW
Trial: 29767728
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg andecaliximab and placebo
Trial: 25252254
Drug: Oral-B 3D
RxNorm normalized name: Oral-B 3D White Luxe Pulsar Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B 3D White
Trial: 20164411
Drug: Daily reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily reinforcement of speed (DRS) after a single, daily 10-m walk
Trial: 20164411
Drug: Daily reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily reinforcement of speed (DRS)
Trial: 17379123
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine 0.5 mg/kg in 2 mL saline before surgery, followed by continuous IV infusion of ketamine at 6 micro/(kg/min)
Trial: 17379123
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (10 mL/h) until bleeding control, with 0.8 mg/kg ketamine during bleeding control in 2 mL saline
Trial: 15747897
Drug: Adjunctive subantimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive subantimicrobial dose doxycycline (SDD; 20 mg doxycycline twice daily)
Trial: 11874994
Drug: PPI +
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI + 1 day of H2RA (ranitidine 300 mg)
Trial: 11874994
Drug: PPI twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI twice daily alone
Trial: 11874994
Drug: PPI twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI twice daily + H2RA after 1 week
Trial: 28122105
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg orally, once daily) for 10 days
Trial: 28122105
Drug: Acetylcysteine with
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcysteine with amoxicillin‐clavulanic acid, pseudoephedrine, and intranasal normal saline
Trial: 17097398
Drug: Topical retapamulin
RxNorm normalized name: retapamulin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retapamulin ointment 1% (twice daily for 5 days)
Trial: 17097398
Drug: Oral cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin (500 mg twice daily for 10 days)
Trial: 14984435
Drug: TGZ 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGZ 600 mg daily
Trial: 14984435
Drug: TGZ 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGZ 200 mg daily
Trial: 9524792
Drug: Rifaximin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (100 mg every six hours for an average of four days)
Trial: 9524792
Drug: Paromomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin (125 mg every six hours for an average of four days)
Trial: 8292061
Drug: Eryfer 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eryfer 100 (100 mg Fe++)
Trial: 8292061
Drug: Eryfer (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eryfer (50 mg Fe++)
Trial: 29371381
Drug: Inhaled diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled diesel exhaust (DE) combined with allergen exposure
Trial: 29371381
Drug: Inhaled diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled diesel exhaust (DE) alone
Trial: 24560541
Drug: Vaccine (Merck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (Merck Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine)
Trial: 22563210
Drug: Ertapenem, 1
RxNorm normalized name: Ertapenem, 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem, 1 g once daily
Trial: 22563210
Drug: Ceftriaxone, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 2 g once daily
Trial: 12455806
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin 1 gm every 8 hours for 3 days, then oral cephalexin 500 mg every 6 hours for 4 days
Trial: 7085368
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic antibiotics)
Trial: 12455806
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin followed by oral cephalexin
Trial: 10348767
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 g orally once on the first day, followed by 500 mg orally once daily for the next 6 days
Trial: 9780257
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally twice daily for 7 days
Trial: 7589012
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 20 mg i.v. bolus
Trial: 7589012
Drug: Insulin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.15 IU kg-1)
Trial: 2031508
Drug: 5-fluorouracil (5-FU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-FU), 1,200 mg/m2 i.v. infusion over 2 h
Trial: 2031508
Drug: Methotrexate (MTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX), 200 mg/m2 i.v. (push injection), followed 20 h later by 5-FU, 1,200 mg/m2 i.v. infusion over 2 h, plus calcium leucovorin (LV), 25 mg i.m. every 6 h for eight doses beginning 24 h after MTX administration
Trial: 7146823
Drug: Subcutaneous calcium‐heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Trial: 7146823
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K (for 15 days) followed by subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Trial: 7146823
Drug: Subcutaneous calcium‐heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks) started immediately
Trial: 6375891
Drug: Hyposensitization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization treatment with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen
Trial: 2682160
Drug: Hyposensitization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization treatment
Trial: 26508309
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 1000mg orally once daily plus prednisone 5mg orally twice daily
Trial: 20353449
Drug: Interviewer-administered Child-OIDP
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered Child-OIDP
Trial: 20353449
Drug: Self-administered Child-OIDP
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered Child-OIDP
Trial: 11936482
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments pooled
Trial: 10086434
Drug: High-dose methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methadone (80 to 100 mg)
Trial: 10086434
Drug: Moderate-dose methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose methadone (40 to 50 mg)
Trial: 8665532
Drug: Cycloserine treatment
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloserine treatment (various dosages)
Trial: 2694356
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment
Trial: 7004474
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg orally nightly for 1 week
Trial: 7004474
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg rectally nightly for 1 week
Trial: 7004474
Drug: Indomethacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (oral and rectal)
Trial: 7004474
Drug: Indomethacin (oral)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (oral)
Trial: 7004474
Drug: Indomethacin (rectal)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (rectal)
Trial: 30444191
Drug: Combination Treatment
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Treatment (COM)
Trial: 23273827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard attention without specific treatment
Trial: 22331954
Drug: Sunitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib plus docetaxel (sunitinib 37.5 mg/d, days 2 to 15 every 3 weeks; docetaxel 75 mg/m2, day 1 every 3 weeks)
Trial: 22331954
Drug: Docetaxel alone
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel alone (100 mg/m2 every 3 weeks)
Trial: 16973657
Drug: Ciclosporin, Tacrolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin, Tacrolimus, or p55TNFr-Ig (anti-TNF agent)
Trial: 11223695
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium diet (< 600 mg/day)
Trial: 9393299
Drug: TUR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TUR plus BCG therapy
Trial: 7896386
Drug: Folifer and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folifer and calcium tablets supplied from second trimester till delivery along with regular medical supervision and nutrition education.
Trial: 3630961
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement of 100 g/d of mackerel
Trial: 14672296
Drug: Meat supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat supplement
Trial: 28340086
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (10 sessions with licensed massage therapists)
Trial: 17083652
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg of sublingual misoprostol with vaginal placebo (n = 70)